Hamlet BioPharma AB
Hamlet BioPharma AB is a biotechnology company focused on pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.
Business. Hamlet BioPharma AB (HAMLETB.TE) is a biotechnology and medical research company operating within the healthcare sector. The firm focuses on pharmaceuticals and medical research activities, with its primary listing identified by the ticker HAMLETB.TE. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Hamlet BioPharma AB (HAMLETB.TE) is a biotechnology and medical research company operating within the healthcare sector. The firm focuses on pharmaceuticals and medical research activities, with its primary listing identified by the ticker HAMLETB.TE. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Hamlet BioPharma AB has a strong liquidity position, as evidenced by a current ratio of 7.81, indicating that the company holds significantly more current assets than current liabilities. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure with no leverage.
The company's profitability metrics are negative, with a return on equity of -16.18% and a return on assets of -15.23%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit.
Hamlet BioPharma AB's revenue is reported as 0.0 SEK, and the company has not disclosed any specific segments or geographic regions contributing to its operations. The absence of revenue and segment data makes it difficult to assess the company's geographic exposure or revenue concentration.
The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. The absence of revenue and the negative operating and net income figures suggest that the company is in an early stage of development or facing significant operational challenges.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure is currently free of debt, and there are no signs of imminent equity dilution.
There are no recent events or filings disclosed that would provide insight into the company's operations or strategic direction. The absence of recent events or transcripts limits the ability to assess the company's current status or future plans.
- Hamlet BioPharma AB has a strong liquidity position with a current ratio of 7.81 and no long-term debt.
- The company is not generating returns for shareholders, with a return on equity of -16.18% and a return on assets of -15.23%.
- The company's revenue is reported as 0.0 SEK, and there is no disclosed segment or geographic revenue data.
- The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance.
- The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Hamlet BioPharma AB Market data — financials · 2026-05-28